# ScoreItem: DHEA-S - Homens (60-69 anos)

**ID:** `019bf31d-2ef0-7647-abd4-719937d54eb6`
**FullName:** DHEA-S - Homens (60-69 anos) (Exames - Laboratoriais)
**Unit:** µg/dL
**Gender:** male
**Age Min:** 60 anos
**Age Max:** 69 anos

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 9 artigos
- Avg Similarity: 0.696

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7647-abd4-719937d54eb6`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7647-abd4-719937d54eb6",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** DHEA-S - Homens (60-69 anos) (Exames - Laboratoriais)
**Unidade:** µg/dL
**Gênero:** male
**Faixa Etária:** 60-69 anos

**30 chunks de 9 artigos (avg similarity: 0.696)**

### Chunk 1/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.748

composition with metabolism and disease. J Nutr Health Aging 2005;9:408–419
86. Berkman LF, Seeman TE, Albert M et al. High, usual and impaired functioning in
community-dwelling older men and women: Findings from the MacArthur Foundation
Research Network on Successful Aging. 
J Clin Epidemiol 1993;46:1129–1140
87. Morrison MF, Katz IR, Parmelee P et al. 
Dehydroepiandrosterone sulfate (DHEA-S) and
psychiatric and laboratory measures of frailty in a residential care population. Am J Geriatr
Psychiatry 1998;6:277–284
88. Abbasi A, Duthie EH, Sheldahl L et al. Association of dehydroepiandrosterone sulfate,
body composition, and physical fitness in independent communitydwelling older men and
women. J Am Geriatr Soc 1998;46:263–273
89. Clarke BL, Ebeling PR, Jones JD, Wahner HW, O’Fallon WM, Riggs BL, Fitzpatrick LA.
Predictors of bone mineraldensity in aging healthy men varies by skeletal site. Calcified Tiss
Int 2002;70:137–145
90.

---

### Chunk 2/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** discussion | **Similarity:** 0.723

ffect of Dehydroepiandrosterone
on Muscle Strength and Physical Function in Older Adults: A Systematic Review. J Am
Geriatr Soc 2011;59:997–1002
75. Kritz-Silverstein D, von Mühlen D, Gail A. Laughlin GA, Bettencourt R. Effects of
dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA
and well-ness (DAWN) trial. J Am Geriat Soc 2008;56:1292–8
76. Panjari M, Bell RJ, Jane F, et al..A randomized trial of oral DHEA treatment for sexual
function, well-being, and menopausal symptoms in postmenopausal women with low libido. J
Sex Med 2009; 6: 2579–2590
77. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and metaanalysis of
randomized placebo-controlled trials of DHEA treatment effects on quality of life in women
with adrenal insufficiency.
J Clin Endocrinol Metab 2009;94:3676–81
78. Labrie F, Archer D, Bouchard C, et al.

---

### Chunk 3/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.720

ement
in healthy men with age-related decline of DHEA-S: Effects on fat distribution, insulin
sensitivity and lipid metabolism. Aging Male 2003; 6:151–156
27

108. Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio
B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: Effects on
body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol
Metab 2001;86:1968– 1972
109. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G.
Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab
1999;84:1527–1533
110. Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE, Fardeau
M, Marini JF. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-
year-old individuals on muscle function and cross-sectional area: A double-blind placebo-
controlled trial. Arch Int Med 2003;163:720–727
111.

---

### Chunk 4/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.717

men. Age Ageing 2009;38:401–406
70. Baulieu E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate,
and aging: contribution of the DHEAge study to a sociobiomedical issue. Proc Nat Acad Natl
Sci 2000;97:4279–84
71. Ohlsson C, Labrie F, Barrett-Connor E, Karlsson MK, Ljunggren O, et al. Low serum
levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in
elderly Swedish men. J Clin Endocrinol Metab 2010; 95: 4406–4414
72. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF (1999) DHEA and DHEA-S: a
review. 
J Clin Pharmacol 39: 327–348
73. Nair KS, Rizza RA, O’Brien P, et al. 
DHEA in elderly women and DHEA or testosterone
in elderly men. N Engl J Med 2006;355:1647–1659
74. William L. Baker, Shobha Karan, and Anne M. Kenny Effect of Dehydroepiandrosterone
on Muscle Strength and Physical Function in Older Adults: A Systematic Review. J Am
Geriatr Soc 2011;59:997–1002
75. Kritz-Silverstein D, von Mühlen D, Gail A.

---

### Chunk 5/30
**Article:** Serum levels of dehydroepiandrosterone sulfate are associated with a lower risk of mobility-subtype frailty in older Japanese community-dwellers (2022)
**Journal:** Archives of Gerontology and Geriatrics
**Section:** abstract | **Similarity:** 0.717

Estudo prospectivo com 1.886 idosos da comunidade (60-91 anos) demonstrou que níveis séricos mais elevados de DHEA-S foram associados a menor risco de fragilidade, especialmente fragilidade do subtipo mobilidade. A análise de medidas repetidas confirmou que a manutenção de níveis adequados de DHEA-S ao longo do tempo está inversamente relacionada ao desenvolvimento de fragilidade em idosos vivendo na comunidade, sugerindo papel protetor deste hormônio na preservação da função física.

---

### Chunk 6/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.713

n in the analysis. However, the potential inﬂuence of such metabolic factors on DHEA supplementation outcomes could introduce bias. Despite this, sensitivity analyses indicated that no single study disproportionately aﬀected the overall results, supporting the robustness of our conclusions.Our review did not account for these metabolic and comorbidity-related factors, which future research should control for or report in detail to minimize bias. Additionally, sensitivity analyses addressing these vari-ables would be valuable in future meta-analyses.Conclusionis meta-analysis found that DHEA supplementation at doses of 50 mg/day or higher signiﬁcantly increased testosterone levels, and in participants aged 60 years or older, signiﬁcantly elevated estradiol levels.

---

### Chunk 7/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.712

-I and testosterone in
healthy active elderly people. Eur J Appl Physiol 2000;82:83–90
67. Ravaglia G, Forti P, Maioli F, Boschi F, Cicognani A, Bernardi M, Pratelli L, Pizzoferrato
A, Porcu S, Gasbarrini G. Determinants of functional status in healthy Italian nonagenarians
and centenarians: A comprehensive functional assessment by the instruments of geriatric
practice. J Am Geriatr Soc 1997;45:1196–1202
68. Leng SX, Cappola AR, Anderson RE et al. Serum levels of insulin-like growth factor-I
(IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum
interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res 2004;16:153–157
69. Voznesensky M, Walsh S, Dauser D et al. The association between
dehydroepiandosterone and frailty in older men and women. Age Ageing 2009;38:401–406
70. Baulieu E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate,
and aging: contribution of the DHEAge study to a sociobiomedical issue.

---

### Chunk 8/30
**Article:** Dehydroepiandrosterone and its Sulfate Predict the 5-Year Risk of Coronary Heart Disease Events in Elderly Men (2014)
**Journal:** Journal of the American College of Cardiology
**Section:** abstract | **Similarity:** 0.709

Estudo prospectivo com 2.416 homens idosos (69-81 anos) seguidos por 5 anos demonstrou que níveis séricos baixos de DHEA e DHEA-S predizem risco aumentado de eventos de doença coronariana. Ambos DHEA e DHEA-S foram inversamente associados com risco ajustado por idade de evento coronariano (hazard ratios por SD de aumento: 0.82 e 0.86, respectivamente). Os níveis baixos de DHEA-S foram particularmente preditivos em homens mais jovens dentro da coorte, sugerindo que a mensuração de DHEA-S pode ter valor prognóstico cardiovascular em homens na quinta e sexta décadas de vida.

---

### Chunk 9/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.708

208
]. In humans studies, however, the results  are
rather inconsistent. In some studies, the lower levels of DHEA seen with aging have been
associated with impaired glucose tolerance, insulin resistance and diabetes [
212
-
215
], while
in another [
216
] exactly the opposite relation was shown as higher levels of DHEA were
13

associated with impaired glucose tolerance and diabetes mellitus in post-menopausal
women. The truth regarding DHEA/DHEAS and insulin resistance and its associated
conditions gets even more complicated considering conflicting results from interventional
studies with DHEA replacement. Thus, an ameliorating effect of long-term treatment with
DHEA on insulin resistance was described in a group of middle-aged hypo-adrenal women
treated with DHEA [
217
], but also in groups of elderly men [
97
] and postmenopausal women
[
97,217-220
] replaced with DHEA.

---

### Chunk 10/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.703

sterone (DHEA) and its active metabolite DHEA sulfate (DHEAS), are
steroid hormones synthesized and excreted primarily by the 
zona reticularis
 of the adrenal
cortex in response to adrenocorticotropic hormone (ACTH). They exert weak androgenic
effects and are therefore considered precursor hormones that need to be transformed to
potent androgens or estrogens to exert their effects. The potential clinical roles of
DHEA/DHEAS have been studied extensively, as previous epidemiologic and prospective
studies associated the age-related decrease of DHEA/DHEAS levels with higher prevalence
of degenerative disorders and increased frailty and mortality from all causes in the elderly,
attributing to adrenal androgens anti-ageing properties. But do they really suggest that they
are hormones related to longevity or just another pointless alchemy against ageing?

---

### Chunk 11/30
**Article:** A Review of Age-Related Dehydroepiandrosterone Decline and Its Association with Well-Known Geriatric Syndromes: Is Treatment Beneficial? (2013)
**Journal:** Rejuvenation Research
**Section:** abstract | **Similarity:** 0.702

Revisão abrangente sobre o declínio de DHEA relacionado à idade e associações com síndromes geriátricas. Níveis de DHEA variam entre 1,33-7,78 ng/mL entre 18-40 anos, declinando para 10-20% desses valores aos 70-80 anos. Associações primárias incluem deterioração musculoesquelética (força muscular, densidade óssea), declínio cognitivo, transtornos de humor e risco cardiovascular.

---

### Chunk 12/30
**Article:** Dehydroepiandrosterone Supplementation in Elderly Men: A Meta-Analysis Study of Placebo-Controlled Trials (2013)
**Journal:** The Journal of Clinical Endocrinology & Metabolism
**Section:** abstract | **Similarity:** 0.702

Meta-análise de ensaios clínicos randomizados controlados por placebo avaliando suplementação de DHEA em homens idosos. Os resultados não demonstraram efeito da suplementação de DHEA em comparação com placebo para diversos parâmetros clínicos incluindo metabolismo lipídico e glicêmico, saúde óssea, função sexual e qualidade de vida. A suplementação foi associada à redução da massa gorda, porém este efeito depende estritamente da conversão do DHEA em metabólitos bioativos como andrógenos ou estrogênios.

---

### Chunk 13/30
**Article:** MFI - Reposição Hormonal - AULA 01 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.698

80 anos com testosterona de 500-600, sugerindo que seus níveis de pico na juventude poderiam ter sido muito mais altos (ex: 1.500).
*   **Declínio Hormonal Feminino e DHEA**
    - Mulheres também experimentam um declínio na testosterona, que é produzida pelos ovários e adrenais. A queda pode ser menos linear que nos homens, pois a produção adrenal pode ser preservada.
    - O DHEA (deidroepiandrosterona), um pró-hormônio precursor, diminui nitidamente com a idade, indicando um "desgaste" da glândula adrenal.
    - A prescrição de DHEA (prasterona no Brasil) é feita em comprimidos (forma mais estudada) ou creme (forma mais fisiológica). Doses para mulheres são menores (10-15mg) para evitar conversões indesejadas. Para homens, sua função como estimulador de outros hormônios é menos estabelecida.
### 4.

---

### Chunk 14/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.692

:4279–
84
21

18. Mazat  L,  Lafont  S,  Berr  C,  Debuire  B,  Tessier  JF,  Dartigues  JF,  et  al.
Prospective measurements  of  dehydroepiandrosterone  sulfate  in  a  cohort  of  elderly
subjects:  relationship  to  gender,  subjective  health,  smoking  habits,  and 10-year
mortality.  Proc  Natl  Acad  Sci  U  S  A  2001;98:8145–50
19. Heaney JL, Phillips AC, Carroll D. Ageing, physical function, and the diurnal rhythms of
cortisol and dehydroepiandrosterone.Psychoneuroendocrinology. 2012;37(3):341-9
20. Laughlin, G. A. and Barrett-Connor, E. Sexual dimorphism in the influence of advanced
aging on adrenal hormone levels: the Rancho Bernardo Study. J Clin Endocrinol Metab
2000;85:3561-3568
21. Baulieu  EE.  Androgens  and  aging  men.  Mol  Cell  Endocrinol  2002;198:41–9
22. 
Parker, C.R. Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in
the human adrenal during development and aging. Steriods 1999;64, 640—647
23. Yen, S.S.C., Laughlin, G.A.

---

### Chunk 15/30
**Article:** Serum concentrations of oxytocin, DHEA and follistatin are associated with osteoporosis or sarcopenia in community-dwelling postmenopausal women (2021)
**Journal:** BMC Geriatrics
**Section:** results | **Similarity:** 0.692

andgaitspeed.Furtherresultsshowedthatpostmeno-pausalwomenwithsarcopeniaweremorelikelytohavehigherDHEAlevels.However,T2andE2werenotre-latedtomusclemass,gripstrengthorgaitspeed.TheseresultssuggestedthatthecirculatingsexhormonesDHEAwasabetterbiomarkerthanT2andE2formusclestrengthandgaitspeed,whichlikelyoccurredbecauseDHEAisaprecursorforsexsteroids.Threerea-sonsmaysupportthishypothesis.First,DHEAdoesnotbindtosexhormone-bindingglobulin(SHBG),whichsuggeststhatDHEAhasfreeaccesstotargetorganscomparedtoSHBG-boundE2andT2[24].Second,DHEAisanandrogenprehormoneproducedinthezonareticularisofthefemaleadrenalglandandovarianthecacells,anditactsasanupstreamprecursorofT2andE2inpostmenopausalwomen[25].DHEAinpostmeno-pausalwomenbecomesthepredominantsexhormoneinsteadofE2[26].CirculatingDHEAprovidessubstratesthatarerequiredforconversionintopotentandrogensandestrogensinperipheraltissues.SkeletalmusclesarecapableofsynthesizingandrogensandestrogensfromDHEA[27].Therefore,TandE2levelsinserumdonotrepresenttheconcen

---

### Chunk 16/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.692

Stanczyk FZ, Bairey Merz CN. DHEA-S levels and
cardiovascular disease mortality in postmenopausal women: Results from the National
Institutes of Health–National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s
Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 2010;95:4985–4992
204. Christiansen JJ, Andersen NH, Sørensen KE, Pedersen EM, Bennett P, Andersen M,
Christiansen JS, Jørgensen JO, Gravholt CH. Dehydroepiandrosterone substitution in
female adrenal failure: no impact on endothelial function and cardiovascular parameters
despite normalization of androgen status. Clin Endocrinol 2007;66:426–433
205. Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of
oral DHEA therapy for postmenopausal women. Maturitas 2009;63:240–245
206. Cleary MP, Zisk JF. Anti-obesity effect of two different levels of
dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes
1986;10:193–204
207.

---

### Chunk 17/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** discussion | **Similarity:** 0.691

asures [
27]
.
Since DHEA is the main source of androgens in women, its age-related decline leads to a
corresponding decrease in the total androgen pool. Although there is actually no defined
level of androgen below which women can be said to be deficient, the decline of DHEA in
postmenopausal women would 
suggest
 they are “deficient” in both estrogens and androgens
[16]. The declining circulating levels of adrenal androgens with advancing age have been
related to clinical symptoms and disorders (see below).
In the last few years, the concept that adrenal androgen production gradually declines with
advancing age has changed following the analysis of the longitudinal data collected in the
Study of Women’s Health Across the Nation (SWAN) [28].

---

### Chunk 18/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.689

dose dehydroepiandrosterone affects
behavior in hypopituitary androgen-deficient women: a placebocontrolled trial. J Clin
Endocrinol Metab 2002;87:2046
144. van Thiel SW, Romijn JA, Pereira AM, et al. Effects of dehydroepiandrostenedione,
superimposed on growth hormone substitution, on quality of life and insulin-like growth factor
I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-
over trial. J Clin Endocrinol Metab 2005;90:3295–303
145. Lovas K, Gebre-Medhin G, Trovik T, et al. Replacement of dehydroepiandrosterone in
adrenal failure: no benefit for subjective health status and sexuality in a 9-month randomized
parallel group clinical trial. J Clin Endocrinol Metab 2003;88:1112–8
146. Avis NE, Brockwell S, Randolph Jr JF, et al. Longitudinal changes in sexual functioning
as women transition through menopause: results from the Study of Women’s Health Across
the Nation. Menopause 2009;16:442–52
147.

---

### Chunk 19/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** other | **Similarity:** 0.688

verted into its sulfated form, DHEA sulfate (DHEA-S), which circulates at much higher concentrations and can be further metabolized into active sex hormones as needed [5].DHEA levels decline signiﬁcantly with age, decreasing by approximately 70% between the ages of 20 and 60, pri-marily due to reduced adrenal production. DHEA sup-plementation has been explored as an adjunct therapy for postmenopausal women, alongside hormone replace-ment therapy (HRT), and has demonstrated potential beneﬁts in improving metabolic and endocrine function, as well as sexual health [6]. DHEA exerts androgenic, estrogenic, and steroidal eﬀects and has been associated with various biological functions, including antioxidant properties, neuroprotection, and anticancer activity [7].

---

### Chunk 20/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.687

randomized clinical trials. Exp Gerontol. 2020;141: 111110. 41. Zhu Y, Qiu L, Jiang F, Găman M-A, Abudoraehem OS, Okunade KS, et al. The eﬀect of dehydroepiandrosterone (DHEA) supplementation on estradiol levels in women: a dose-response and meta-analysis of randomized clinical trials. Steroids. 2021;173:108889. 42. Jamka K, Adamczuk P, Skowronska A, Bojar I, Raszewski G. Assess-ment of the eﬀect of estradiol on biochemical bone turnover markers among postmenopausal women. Ann Agric Environ Med. 2021;28(2):7896. 43. Clark BJ, Prough RA, Klinge CM. Mechanisms of action of dehydroepi-androsterone. Vitam Horm. 2018;108:2973. 44. Brzozowska M, Lewiński A. Changes of androgens levels in meno-pausal women. Menopause Review/Przegląd Menopauzalny. 2020;19(4):1514. 45. Nair KS, Rizza RA, OBrien P, Dhatariya K, Short KR, Nehra A, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355(16):164759. 46. Villareal DT, Holloszy JO.

---

### Chunk 21/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.684

was further supported by the results of Eggers regression test.Discussionis meta-analysis of randomized controlled trials (RCTs) evaluated the eﬀects of dehydroepiandrosterone (DHEA) supplementation on testosterone and estradiol levels in postmenopausal women. Our analysis of 21 RCTs revealed that DHEA supplementation signiﬁcantly increased both testosterone and estradiol concentrations, although substantial heterogeneity was observed across the included trials.Our ﬁndings indicate that DHEA is particularly eﬀec-tive in elevating testosterone levels when administered at dosages  50 mg/day. Additionally, a marked increase in estradiol levels was noted among participants aged  60 years receiving the same dosage. ese ﬁndings 
Fig. 2 Forest plot of the randomized controlled trials investigating the eﬀect of dehydroepiandrosterone (DHEA) supplementation on serum estradiol concentrations

Page 9 of 13
Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
Fig.

---

### Chunk 22/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.684

sely associated with glucose concentration in the medium. J Steroid Biochem Mol Biol. 2000;75(23):15966. 8. De Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB. Dehydroepiandrosterone, its sulfate and cognitive functions. Clin Pract Epidemiol Ment Health CP EMH. 2016;12:24. 9. Ma Y, Fan X, Han J, Cheng Y, Zhao J, Fang W, et al. Critical illness and sex hormones: response and impact of the hypothalamicpituitarygonadal axis. Therap Adv Endocrinol Metab. 2025;16:20420188251328190. 10. Kawakita T, Yasui T, Yoshida K, Matsui S, Iwasa T. Correlations of andros-tenediol with reproductive hormones and cortisol according to stages during the menopausal transition in Japanese women. J Steroid Biochem Mol Biol. 2021;214: 106009. 11. Colldén H, Nilsson ME, Norlén A-K, Landin A, Windahl SH, Wu J, et al. Dehydroepiandrosterone supplementation results in varying tissue-speciﬁc levels of dihydrotestosterone in male mice. Endocrinology. 2022;163(12):163. 12.

---

### Chunk 23/30
**Article:** Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women (2025)
**Journal:** Clinical Endocrinology
**Section:** abstract | **Similarity:** 0.682

Diretriz clínica da Society for Endocrinology para avaliação de excesso androgênico em mulheres. DHEA-S sérico é a medida mais confiável de produção adrenal de andrógenos, particularmente útil na transição perimenopáusica. Aproximadamente 25% da produção androgênica ocorre nas adrenais em mulheres pré-menopáusicas, aumentando para 100% na pós-menopausa. Declínio de DHEA-S inicia aos 30 anos devido à involução da zona reticular adrenal.

---

### Chunk 24/30
**Article:** MFI - Reposição Hormonal - AULA 01 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.681

reavaliar a cada 6–8 semanas, checar SHBG, estradiol, DHT se pertinente) para padronizar seguimento.
### 8. DHEA (prasterona): papel, prescrição e diferenças entre sexos
- DHEA/DHEA-S: pró-hormônio, não considerado hormônio pleno; declínio com a idade, especialmente adrenal.
- Em mulheres, pode estimular hormônios subsequentes; em homens, não costuma ter função robusta para estimular outros hormônios.
- No Brasil, prescrição como prasterona; estudos principalmente com comprimido; creme seria mais fisiológico, porém menos estudado; ambas formas possíveis.
- Doses mulheres: baixas (10–15 mg) e monitorar porque pode elevar hormônios indesejados; utilidade em infertilidade/autoimunes com dose básica.
- Conceito de “desgaste” glandular ao longo da vida aplicável às adrenais.
> **Sugestões de IA**
> - Organização: Você delimitou bem diferenças por sexo; inclua critérios claros de quando considerar prasterona (indicações vs quando evitar).

---

### Chunk 25/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.680

man  HA,  Johannes  CB,  Araujo  AB,  Mohr  BA,  Longcope  C,  McKinlay  JB.
Low dehydroepiandrosterone  and  ischemic  heart  disease  in  middle-aged  men:
prospective  results  from  the  Massachusetts  Male  Aging  Study.  Am  J  Epidemiol
2001;153:79–89
246. Trivedi  DP,  Khaw  KT.  Dehydroepiandrosterone  sulfate  and  mortality  in elderly
men  and  women.  J  Clin  Endocrinol  Metab  2001;86:4171–7
247. Hak  AE,  Witteman  JC,  de  Jong  FH,  Geerlings  MI,  Hofman  A,  Pols  HA.  Low
levels of  endogenous  androgens  increase  the  risk  of  atherosclerosis  in  elderly  men:
the  Rotterdam  study.  J  Clin  Endocrinol  Metab  2002;87:3632–9
248. Herrington  DM,  Gordon  GB,  Achuff  SC,  Trejo  JF,  Weisman  HF,  Kwiterovich  Jr
PO,  et  al.  Plasma  dehydroepiandrosterone  and  dehydroepiandrosterone  sulfate  in
patients  undergoing  diagnostic  coronary  angiography.  J  Am  Coll Cardiol  1990;16:862–
70
249.

---

### Chunk 26/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.671

changes
in circulating estradiol and progesterone [
32
], the perimenopausal rise in adrenal androgens
could potentially suggest a more important role of these hormones in the occurrence of
symptoms during the menopausal transition [
33
]. The observational, epidemiologic, and
interventional studies addressing this hypothesis are analyzed below.
1f. Biologic effects of Adrenal Androgens; Cellular and molecular actions  
Role as pro-hormones
DHEA
 
possesses pleiotropic effects. Epidemiologic 
and prospective studies have associated
the decline of circulating levels of androgens with the development and progression of
degenerative disorders.
 The exact mechanism of action and clinical role of DHEA and
6

DHEAS, if any, remain unclear. 
Due to lack or only minor inherent steroidogenic activity, the
adrenal androgens 
need to be transformed to potent androgens or estrogens to exert their
effects on peripheral tissues.

---

### Chunk 27/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.671

h and physical function but not bone mineral density in frail older women. J
Am Geriatr Soc 2010;58:1707–1714
114. Muller M, van den Beld AW, van der Schouw YT et al. Effects of
dehydroepiandrosterone and atemestane supplementation on frailty in elderly men. J Clin
Endocrinol Metab 2006;91:3988–3991
115. Villareal DT, Holloszy JO. DHEA enhances effects of weight training on muscle mass
and strength in elderly women and men. Am J Physiol Endocrinol Metab 2006;291:E1003–
E1008
116. Percheron G, Hogrel JY, Denot-Ledunois S et al. Effect of 1-year oral administration of
dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-
sectional area. A double-blind placebo-controlled trial. Arch Intern Med 2003;163:720–727
117. Arlt W, Callies F, Koehler I et al. Dehydroepiandrosterone supplementation inhealthy
men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol
Metab 2001;86:4686–4692
118.

---

### Chunk 28/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.671

HEA) supplementation on serum levels of insulin-like growth factor 1 (IGF-1): a dose-response meta-analysis of randomized controlled trials. Exp Gerontol. 2020;136:110949. 4. Mohamad N-V, Razali N-SC, Shamsuddin N-AM. Dehydroepiandros-terone and bone health: mechanisms and insights. Biomedicines. 2024;12(12):2780. 5. Mueller JW, Gilligan LC, Idkowiak J, Arlt W, Foster PA. The regula-tion of steroid action by sulfation and desulfation. Endocr Rev. 2015;36(5):52663. 6. Tang J, Chen L-R, Chen K-H. The utilization of dehydroepiandrosterone as a sexual hormone precursor in premenopausal and postmenopausal women: an overview. Pharmaceuticals. 2021;15(1):46. 7. Yang N-C, Jeng K-CG, Ho W-M, Chou S-J, Hu M-L. DHEA inhibits cell growth and induces apoptosis in BV-2 cells and the eﬀects are inversely associated with glucose concentration in the medium. J Steroid Biochem Mol Biol. 2000;75(23):15966. 8. De Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB.

---

### Chunk 29/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** discussion | **Similarity:** 0.669

o-
DHEA ratios among working individuals. Yonsei Med J 2010; 51: 212–218
175. Lennartsson A-K, Theorell T, Rockwood AL, Kushnir MM, Jonsdottir IH Perceived
Stress at Work Is Associated with Lower Levels of DHEA-S. PloS ONE 2013;  8: e72460
176. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis.Neurology 1998;
51:728-33
177. Lu SF, Mo Q, Hu S, Garippa C, Simon NG. Dehydroepiandrosterone upregulates
neural androgen receptor level and transcriptional activity. J Neurobiol 2003;57:163–71
178. Suzuki M, Wright LS, Marwah P, Lardy HA, Svendsen CN. Mitotic and neurogenic
effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from
the fetal cortex. Proc Natl Acad Sci USA 2004;101:3202–3207
179. Lang PO, Lapenna A, Pitts D, Aspinall R. Immunological pathogenesis of main age-
related diseases and frailty: Role of immunosenescence. Eur Ger Med 2010;1:112–121
180. 
Davis SR
,
 
Shah SM
,
 
McKenzie DP
,
 
Kulkarni J
,
 
Davison SL
,
 
Bell RJ
.

---

### Chunk 30/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.669

/ doi. org/ 10. 1046/j. 1365- 2265. 1998. 00507.x. 38. Kudielka BM, Hellhammer J, Hellhammer DH, Wolf OT, Pirke KM, Varadi E, et al. Sex diﬀerences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a 2-week dehydroepiandrosterone treatment. J Clin Endocrinol Metab. 1998;83(5):175661. https:// doi. org/ 10. 1210/ jcem. 83.5. 4758. 39. Casson PR, Faquin LC, Stentz FB, Straughn AB, Andersen RN, Abra-ham GE, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril. 1995;63(5):102731. 40. Li Y, Ren J, Li N, Liu J, Tan SC, Low TY, et al. A dose-response and meta-analysis of dehydroepiandrosterone (DHEA) supplementation on testosterone levels: perinatal prediction of randomized clinical trials. Exp Gerontol. 2020;141: 111110. 41. Zhu Y, Qiu L, Jiang F, Găman M-A, Abudoraehem OS, Okunade KS, et al.

---

